Therapies targeting novel inhibitory and stimulatory immunecheckpoints have been shown to possess substantial therapeutic potential, bothas monotherapies and in combination with other interventions, across multipledisease interventions
Roots Analysis is pleased toannounce the publication of its recent study, titled, “Next Generation Immune CheckpointInhibitors and Stimulators Market, 2020-2030.”
Thereport features an extensive study of the current market landscape, offering aninformed opinion on the likely adoption of these therapies over the nextdecade. It features an in-depth analysis, highlighting the capabilities ofvarious stakeholders engaged in this domain. In addition to other elements, thestudy includes:
§ Adetailed assessment of the current market landscape of drug developers engagedin the development of next generation immune checkpoint modulators.
§ Adetailed analysis of more than 590 completed, ongoing and planned clinicalstudies of next generation immune checkpoint inhibitors and stimulators.
§ Detailedprofiles of developers of next generation immune checkpoint modulators (shortlistedon the basis of the number of pipeline products).
§ Anin-depth analysis of more than 490 grants that have been awarded to researchinstitutes engaged in next generation immune checkpoint therapy-relatedprojects.
§ Ananalysis of the partnerships that have been established in this domain, in therecent past.
§ A competitivenessanalysis of biological targets, featuring insightful pictorial summaries andrepresentations.
§ Ananalysis of the initiatives of big biopharma players engaged in this domain.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
- Target Disease Indication
§ BreastCancer
§ ChronicLymphocytic Leukemia
§ ColorectalCancer
§ Headand Neck Cancer
§ LungCancer
§ LupusNephritis
§ Melanoma
§ MultipleMyeloma
§ PrimarySjögren's Syndrome
§ Others
- Target Immune Checkpoint
§ B7-H3
§ CD38
§ CD40
§ CD47
§ Others
- Mechanism of Action
§ Inhibitory
§ Stimulatory
- Therapeutic Modality
§ MonoclonalAntibody
§ SmallMolecule
- Type of Therapy
§ Monotherapy
§ CombinationTherapy
- Route of Administration
§ Intravenous
§ Subcutaneous
§ Others
- Key Geographical Region
§ NorthAmerica
§ Europe
§ Asia-Pacificand the Rest of the World
ToRequest for sample report - https://www.rootsanalysis.com/reports/303/request-sample.html
Keycompanies covered in the report
§ Bristol Myers Squibb
§ GlaxoSmithKline
§ Incyte
§ Novartis
§ Trillium Therapeutics
Formore information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Other Recent Offerings
1. NeoantigenTargeted Therapies Market, 2019-2030
2. BispecificAntibody Therapeutics Market (4th Edition), 2019-2030
3. GlobalStem Cells Market: Focus on Clinical Therapies, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter- https://twitter.com/RootsAnalysi
